Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
2006

Anticancer Effects of Hydralazine and Valproic Acid

publication Evidence: moderate

Author Information

Author(s): Chavez-Blanco Alma, Perez-Plasencia Carlos, Perez-Cardenas Enrique, Carrasco-Legleu Claudia, Rangel-Lopez Edgar, Segura-Pacheco Blanca, Taja-Chayeb Lucia, Trejo-Becerril Catalina, Gonzalez-Fierro Aurora, Candelaria Myrna, Cabrera Gustavo, Duenas-Gonzalez Alfonso

Primary Institution: Unidad de Investigación Biomédica en Cancer. Instituto de Investigaciones Biomédicas, UNAM, /Instituto Nacional de Cancerología, Mexico City, Mexico

Hypothesis

The study aims to evaluate the combined antineoplastic effect of hydralazine and valproic acid in cancer cell lines.

Conclusion

Hydralazine and valproic acid have promising antineoplastic effects when used together and may enhance the effectiveness of existing chemotherapy drugs.

Supporting Evidence

  • Valproic acid showed a strong growth inhibitory effect in various cancer cell lines.
  • Hydralazine alone had no growth inhibitory effect on the tested cancer cell lines.
  • The combination of hydralazine and valproic acid increased the cytotoxicity of chemotherapy drugs like gemcitabine and adriamycin.

Takeaway

Hydralazine and valproic acid, two common medications, can work together to help fight cancer better than when used alone.

Methodology

The study involved treating various cancer cell lines with hydralazine and valproic acid, both separately and in combination, and measuring their growth inhibition and gene expression changes.

Statistical Information

P-Value

p < 0.002

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1186/1475-2867-6-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication